Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Takimoto · SciRah

Researcher profile · Semantic Scholar

C. Takimoto

Share profile

C. Takimoto — researcher profile on SciRah

h-index: 48
Works: 258
Citations: 12K

Most-cited papers

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
R. Advani, I. Flinn, L. Popplewell, A. Forero +17 more
2018New England Journal of Medicine919 citations Open access
Semantic Scholar
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
R. Maki, D. D'Adamo, M. Keohan, M. Saulle +16 more
2009Journal of Clinical Oncology546 citations Open access
Semantic Scholar
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
B. Sikic, N. Lakhani, A. Patnaik, Sumit A. Shah +26 more
2016Journal of Clinical Oncology476 citations Open access
Semantic Scholar
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
K. Pienta, J. Machiels, D. Schrijvers, B. Alekseev +9 more
2013Investigational new drugs385 citations
Semantic Scholar
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
A. Tolcher, A. Mita, L. Lewis, C. Garrett +8 more
2008Journal of Clinical Oncology253 citations Open access
Semantic Scholar
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Mark P. Chao, C. Takimoto, Dong-Dong Feng, K. McKenna +5 more
2020Frontiers in Oncology227 citations Open access
Semantic Scholar
Castration-Resistant Prostate Cancer: Locking Up the Molecular Escape Routes
R. Attar, C. Takimoto, M. Gottardis
2009Clinical Cancer Research216 citations
Semantic Scholar
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
D. Sallman, A. Asch, M. A. Al Malki, D. Lee +12 more
2019Blood187 citations
Semantic Scholar
Dietary genistein inhibits metastasis of human prostate cancer in mice.
M. Lakshman, Li Xu, V. Ananthanarayanan, J. Cooper +4 more
2008Cancer Research182 citations Open access
Semantic Scholar
Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials
C. Takimoto, A. Awada
2008Cancer Chemotherapy and Pharmacology163 citations
Semantic Scholar
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
S. Goel, A. Mita, M. Mita, E. Rowinsky +8 more
2009Clinical Cancer Research151 citations Open access
Semantic Scholar
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors
A. Mita, C. Takimoto, M. Mita, A. Tolcher +10 more
2010Clinical Cancer Research100 citations Open access
Semantic Scholar
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
D. Sallman, M. A. Al Malki, A. Asch, D. Lee +14 more
202073 citations
Semantic Scholar
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
Dong-Dong Feng, Gip Phung, K. McKenna, Feifei Zhao +11 more
2018Blood71 citations Open access
Semantic Scholar
Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase 1 NCI Organ Dysfunction Working Group Study NCI-6432
P. LoRusso, K. Venkatakrishnan, R. Ramanathan, J. Sarantopoulos +10 more
2012Clinical Cancer Research66 citations Open access
Semantic Scholar
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.
D. Sallman, W. Donnellan, A. Asch, D. Lee +13 more
2019Journal of Clinical Oncology65 citations
Semantic Scholar
Maximum tolerated dose: clinical endpoint for a bygone era?
C. Takimoto
2009Targeted oncology60 citations
Semantic Scholar
Phase I Study of E7820, an Oral Inhibitor of Integrin α-2 Expression with Antiangiogenic Properties, in Patients with Advanced Malignancies
M. Mita, K. Kelly, A. Mita, A. Ricart +9 more
2011Clinical Cancer Research55 citations Open access
Semantic Scholar
A Phase 1, Dose-Escalation, Pharmacokinetic and Pharmacodynamic Study of BIIB021 Administered Orally in Patients with Advanced Solid Tumors
M. Saif, C. Takimoto, M. Mita, U. Banerji +5 more
2013Clinical Cancer Research45 citations Open access
Semantic Scholar
Dose-Escalating and Pharmacological Study of Bortezomib in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study
T. Leal, S. Remick, C. Takimoto, R. Ramanathan +15 more
2011Cancer Chemotherapy and Pharmacology45 citations Open access
Semantic Scholar
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
G. Fisher, N. Lakhani, C. Eng, J. Hecht +14 more
202039 citations
Semantic Scholar
AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
D. Sallman, A. Asch, S. Kambhampati, M. A. Al Malki +20 more
202138 citations
Semantic Scholar
Utilizing pharmacokinetics/pharmacodynamics modeling to simultaneously examine free CCL2, total CCL2 and carlumab (CNTO 888) concentration time data
Gerald J. Fetterly, Urvi Aras, Patricia D. Meholick, C. Takimoto +8 more
2013Journal of clinical pharmacology36 citations
Semantic Scholar
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
J. Rodón, M. Garrison, L. Hammond, J. de Bono +9 more
2008Cancer Chemotherapy and Pharmacology35 citations
Semantic Scholar
Heat shock proteins: a potential anticancer target.
K. Sankhala, M. Mita, A. Mita, C. Takimoto
2011Current Drug Targets33 citations
Semantic Scholar
A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment
C. Sweeney, C. Takimoto, L. Wood, J. Porter +4 more
2010Cancer Chemotherapy and Pharmacology32 citations
Semantic Scholar
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients
C. Ng, S. Bai, C. Takimoto, M.-T. Tang +1 more
2009Cancer Chemotherapy and Pharmacology32 citations
Semantic Scholar
A phase I study of AVE1642, a humanized monoclonal antibody IGF-1R (insulin like growth factor1 receptor) antagonist, in patients(pts) with advanced solid tumor(ST)
A. Tolcher, A. Patnaik, E. Till, C. Takimoto +6 more
200832 citations
Semantic Scholar
Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies
M. Mita, A. Mita, J. Sarantopoulos, C. Takimoto +6 more
2009Cancer Chemotherapy and Pharmacology31 citations
Semantic Scholar
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
N. Lakhani, A. Patnaik, J. Liao, J. Moroney +12 more
202027 citations
Semantic Scholar
Tesetaxel, a new oral taxane, in combination with capecitabine: a phase I, dose-escalation study in patients with advanced solid tumors
M. Saif, J. Sarantopoulos, A. Patnaik, A. Tolcher +2 more
2011Cancer Chemotherapy and Pharmacology27 citations
Semantic Scholar
THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
R. Advani, N. Bartlett, S. Smith, M. Roschewski +16 more
2019Hematological Oncology26 citations
Semantic Scholar
Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
C. Takimoto
2009Cancer Chemotherapy and Pharmacology25 citations
Semantic Scholar
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.
R. Advani, I. Flinn, L. Popplewell, A. Forero-Torres +11 more
201823 citations
Semantic Scholar
Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors
R. Dienstmann, R. Bahleda, B. Adamo, J. Rodón +13 more
201423 citations
Semantic Scholar
A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies
G. Shapiro, R. Bannerji, Karen A. Small, S. Black +6 more
200823 citations
Semantic Scholar
Improving attribution of adverse events in oncology clinical trials.
G. George, Pedro C. Barata, A. Campbell, Alice Chen +22 more
2019Cancer Treatment Reviews22 citations
Semantic Scholar
Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing
M. Nikanjam, C. Stewart, C. Takimoto, T. Synold +3 more
2015Cancer Chemotherapy and Pharmacology22 citations Open access
Semantic Scholar
The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer
H. Wakelee, C. Takimoto, A. Lopez-Anaya, Q. Chu +9 more
2012Cancer Chemotherapy and Pharmacology20 citations
Semantic Scholar
RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9
James Y. Chen, K. McKenna, T. Choi, Jiaqi Duan +12 more
2018Blood18 citations
Semantic Scholar
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors
Chia-Chi Lin, E. Calvo, K. Papadopoulos, A. Patnaik +12 more
2009Cancer Chemotherapy and Pharmacology18 citations
Semantic Scholar
Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients
J. Latz, K. Schneck, K. Nakagawa, M. Miller +1 more
2009Clinical Cancer Research16 citations
Semantic Scholar
Using Pharmacokinetic and Pharmacodynamic Data in Early Decision Making Regarding Drug Development: A Phase I Clinical Trial Evaluating Tyrosine Kinase Inhibitor, AEE788
J. Baselga, A. Mita, P. Schöffski, H. Dumez +12 more
2012Clinical Cancer Research15 citations Open access
Semantic Scholar
A phase I pharmacokinetic study of bexarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)
J. Rodón, C. Jacobs, Q. Chu, E. Rowinsky +3 more
2012Cancer Chemotherapy and Pharmacology14 citations
Semantic Scholar
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
B. Sikic, N. Lakhani, A. Patnaik, Sumit A. Shah +16 more
201812 citations
Semantic Scholar
Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-in-Class CD20xCD3 Bispecific IgM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies
G. Hernandez, J. So, K. Logronio, M. Kotturi +18 more
2022Blood11 citations Open access
Semantic Scholar
Abstract PR13: The anti-CD47 antibody Hu5F9-G4 is a novel immune checkpoint inhibitor with synergistic efficacy in combination with clinically active cancer targeting antibodies
Mark P. Chao, K. McKenna, Adriel C. Cha, Dong-Dong Feng +6 more
201611 citations
Semantic Scholar
Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients
C. Ng, A. Patnaik, M. Beeram, C. Lin +1 more
2011Cancer Chemotherapy and Pharmacology11 citations
Semantic Scholar
Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.
C. Takimoto
2009European Journal of Cancer11 citations
Semantic Scholar
Open label phase I study of MBP-426, a novel formulation of oxaliplatin, in patients with advanced or metastatic solid tumors.
A. Phan, C. Takimoto, R. Adinin, L. Wood +5 more
200711 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Mark P. Chao×15
Invite
Mark P. Chao — researcher profile on SciRah
J. Volkmer×12
Invite
J. Volkmer — researcher profile on SciRah
M. Mita×9
Invite
M. Mita — researcher profile on SciRah
A. Patnaik×9
Invite
A. Patnaik — researcher profile on SciRah

×9

Invite

A. Tolcher — researcher profile on SciRah

Invite

B. Agoram — researcher profile on SciRah

Invite

A. Mita — researcher profile on SciRah

James Y. Chen×7

Invite

James Y. Chen — researcher profile on SciRah

Invite

R. Majeti — researcher profile on SciRah

J. Sarantopoulos×6

Invite

J. Sarantopoulos — researcher profile on SciRah

Invite

I. Weissman — researcher profile on SciRah

Invite

Jie Liu — researcher profile on SciRah